# COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

> **NCT05692024** · PHASE1,PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Colorectal Cancer
- Coffee
- Gastrointestinal Microbiome
- Stenosis
- Fibrosis, Liver
- Ultrasound Elastography
- Proton Magnetic Resonance Spectroscopy

## Interventions

- **DRUG:** Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05692024
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-21
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05692024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05692024, "COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05692024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*